Evotec's Chief Scientific Officer Dr. Cord Dohrmann Steps Down After 16 Years of Leadership

Transition in Leadership at Evotec

In a significant shift within the scientific leadership of Evotec SE, it has been announced that Dr. Cord Dohrmann, the current Chief Scientific Officer (CSO), will officially step down from his role effective September 30, 2026. This decision, which marks the end of Dr. Dohrmann's 16-year tenure at the company, has been mutual between him and Evotec's management.

Dr. Christian Wojczewski, the Chief Executive Officer, expressed gratitude for Dr. Dohrmann's extensive contributions, highlighting his pivotal role in fostering an environment of scientific excellence and leadership at Evotec. Over his time at the company, Dr. Dohrmann has greatly influenced its trajectory, particularly in developing advanced technologies and innovative strategies that align with the ever-evolving landscape of drug discovery and development. His work in establishing iPSC-based technologies and omics initiatives has fortified Evotec's reputation as a leader in scientific research.

Reflecting on his career at Evotec, Dr. Dohrmann stated, "The landscape of drug development has undergone immense changes over the past 16 years, and I am honored to have played a part in driving that evolution. My experience here has been enriched by the support and collaboration of countless colleagues, and I look forward to witnessing the ongoing success of Evotec in advancing healthcare."

Dr. Dohrmann has held the CSO position since 2010 and is acknowledged for his strategic insights that have led to the strengthening of Evotec's research capabilities. As the firm looks to the future, Evotec is actively engaged in the search for a successor who will continue to uphold and build upon the scientific foundations laid by Dr. Dohrmann.

About Evotec SE

Evotec SE is renowned as a trailblazer in life sciences, focused on advancing drug discovery and development. The firm excels in merging groundbreaking scientific research with innovative, AI-driven technologies to enhance the process from conceptualization to therapeutic application. Their expertise encompasses various domains including small molecules, biologics, and cell therapies, supported by proprietary platforms such as Molecular Patient Databases and iPSC technology.

With flexible partnering arrangements, Evotec collaborates with top pharmaceutical firms, biotech companies, and academic institutions worldwide. Their product offerings range from comprehensive service packages to fully integrated research and development programs. The company’s emphasis on scientific excellence combined with operational flexibility positions it as a formidable player in the life sciences space.

As Evotec continues to innovate and provide significant advancements in therapeutic areas like oncology, cardiovascular conditions, and immunology, Dr. Dohrmann's legacy remains a vital part of its future trajectory. As the company transitions leadership, it stands poised to build upon the strong scientific infrastructure he has developed over his lengthy career.

Read more about Evotec's initiatives and updates on their website and follow them on LinkedIn and X/Twitter @Evotec.